Molecular based strategies to generate protective immune responses to HIV-1

描述(申请人提供)：使用一种新的佐剂设计方法，我们已经确定了一种基于分子的佐剂，它通过几个标准增强免疫应答，包括更早的应答，对疫苗更多部分的更强应答，以及对极少量疫苗的应答能力。该项目的第一阶段涉及将同样的技术应用于艾滋病毒-1抗原。该项目的第二阶段将需要优化我们的佐剂的大规模生产，用于在更大的动物上进行研究，并最终在人类临床试验中进行测试。 与公共卫生相关：该项目寻求进一步描述我们发现的一种新型疫苗佐剂的特征，该佐剂似乎可以增强对困难目标的免疫反应。一旦这种佐剂针对HIV-1目标进行了验证，受益于公共卫生的长期目标将是使用这种佐剂来改进针对流感和疟疾等其他传染病的疫苗策略，以及改进针对癌症患者的治疗性疫苗方法。

DESCRIPTION (provided by applicant): Using a new approach to adjuvant design we have identified a molecular based adjuvant that enhances immune response by several criteria including, an earlier response, a stronger response to more parts of the vaccine, and the ability to respond to very small amounts of vaccine. Phase I of this project involves applying the same technology to HIV-1 antigens. Phase II of the project will entail optimizing large-scale production of our adjuvant for studies in larger animals and eventual testing in human clinical trials. PUBLIC HEALTH RELEVANCE: This project seeks to further characterize a novel vaccine adjuvant that we have discovered that appears to enhance immune responses to difficult targets. Once this adjuvant has been validated against HIV-1 targets, the long-term goal for benefiting public health will be to use this adjuvant to improve vaccine strategies that target other infectious diseases such as Influenza and Malaria in addition to improving therapeutic vaccine approaches for cancer patients.